Status:
RECRUITING
Identify microRNAs in Cachexia in Pancreatic Carcinoma
Lead Sponsor:
University of Oklahoma
Conditions:
Resectable Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Detailed Description
This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospectiv...
Eligibility Criteria
Inclusion
- Male or female patient, who is ≥ 18 years old at the time of informed consent.
- Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
- Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
- Ability to provide written informed consent and HIPAA authorization.
Exclusion
- Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
- Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Key Trial Info
Start Date :
December 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05275075
Start Date
December 7 2022
End Date
May 1 2029
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73117